H.R. 133: Mandating Exclusive Review of Individual Treatments Act

This bill, known as the Mandating Exclusive Review of Individual Treatments Act (MERIT Act), aims to amend how the Medicare program evaluates coverage for drugs and biological products. Specifically, the measure seeks to clarify the national coverage determination process under the Social Security Act. Here are the key components of what the bill proposes:

Key Provisions

• Individual Review Requirement: The bill stipulates that when determining whether a drug or biological product is "reasonable and necessary" for Medicare coverage, the evaluation must be made on an individual basis. This means each drug or biological will be assessed separately rather than grouped together with similar products.

Impact on Medicare Coverage

Under the current framework, the Centers for Medicare & Medicaid Services (CMS) may evaluate a class of drugs or biologicals collectively, potentially limiting access to specific treatments based on broader criteria. This new requirement aims to foster a more tailored and focused approach, possibly allowing more patients access to particular therapies that may be beneficial to their individual health needs.

Context and Rationale

The bill is introduced in response to concerns that some potentially effective treatments may get overlooked when evaluations are done on a class-wide basis. The supporters of the bill assert that this individual review process could improve patient outcomes by ensuring that specific medications are available based on their merits rather than being overshadowed by the characteristics of other similar treatments.

Legislative Journey

The MERIT Act was introduced in the House of Representatives and has undergone various stages of discussion and amendment, indicating a degree of support and potential contention regarding its provisions. The bill has been reported out of committee and is currently designated for further consideration.

Relevant Companies

• PFE (Pfizer Inc.): As a large pharmaceutical company, Pfizer could be affected by changes in coverage for specific drugs and biologicals under Medicare.
• BMRN (BioMarin Pharmaceutical Inc.): If their drugs are subject to individual reviews, it could directly impact their sales and market strategy based on Medicare coverage decisions.
• AMGN (Amgen Inc.): Similar to other biopharmaceutical companies, Amgen may see shifts in Medicare coverage affecting the market availability of its products.